Press release
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies
About this update from Eton Pharmaceuticals, Inc.
[{"type":"text","content":"Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty. DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Ipek Erdogan-Trinkaus as Chief Commercial Officer (CCO). Ms. Erdogan-Trinkaus brings to the Company broad commercial experience in the pharmaceutical industry, spanning leadership, sales, and marketing roles in both large and smaller organizations. She also brings valuable experience within the pediatric endocrinology specialty. At Tolmar Pharmaceuticals, Ms. Erdogan-Trinkaus drove impactful initiatives across various therapeutic areas, including leading strategy and marketing for the successful launch of their rare pediatric endocrinology product FENSOLVI®. During her tenure, she held progressing leadership roles within the commercial organization, with her last appointment being General Manager of the Pediatric Endocrinology business unit. “Ipek is an accomplished leader with a proven track record of overseeing high-performing commercial operations and leading successful rare disease product launches. She joins Eton at a critical time with the anticipated closing of Increlex® in late-December and the expected launch of ET-400 in early 2025. We’re excited to add Ipek’s industry knowledge, experience, and expertise to the management team and I’m confident she will help lead Eton into our next phase of growth,” Sean Brynjelsen, CEO of Eton Pharmaceuticals. “I’m thrilled to step into this role at such a pivotal time for the Company. Eton has a strong commercial infrastructure and a passionate team with deep rare disease expertise in place, along with unique, innovative therapies that make a profound impact in people’s lives. I look forward to working with the talented team to help execute the important near-term launches of Increlex and ET-400, as well as many future launches to come. I’m proud to be part of a truly patient-centric organization deeply committed to bringing life-changing treatme...